An expanded access record providing REGN4461 in Lipodystrophy, Generalized Lipodystrophy (GLD) and Monogenic Obesity (MOB), sponsored by Regeneron Pharmaceuticals. Available. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Regeneron Pharmaceuticals · Expanded access
Provide Expanded Access to REGN4461 for patients with diseases associated with deficient leptin signaling.
Expanded Access requests are only being considered in response to Individual Patient and Intermediate-Size Population EAP Investigational New Drug (IND) applications. Availability will depend on location.
139 studies on the registry are indexed under Lipodystrophy; 10 are open to participants now.
Browse Lipodystrophy studies →Regeneron Pharmaceuticals is the lead sponsor of 411 studies on the registry; 90 are open to participants now.
Of its 125 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion: N/A
Key Exclusion: N/A
To be provided by Regeneron
Also known as: mibavademab
No study locations are listed for this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.
Contact the providerGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.